LadRx Corporation (LADX)
USD 1.61
(-2.42%)
USD 1.61
(-2.42%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 412.28 Thousand USD | 22.15% |
| 2022 | -4.54 Million USD | 17.93% |
| 2021 | -13.16 Million USD | 9.6% |
| 2020 | -6.8 Million USD | 12.02% |
| 2019 | -7.84 Million USD | 4.57% |
| 2018 | -7.33 Million USD | 75.35% |
| 2017 | -26.5 Million USD | 37.84% |
| 2016 | -47.47 Million USD | 23.88% |
| 2015 | -62.96 Million USD | 1.57% |
| 2014 | -29.93 Million USD | -842.6% |
| 2013 | -27.47 Million USD | 69.35% |
| 2012 | -20.93 Million USD | 22.73% |
| 2011 | -22.55 Million USD | -73.6% |
| 2010 | -16.64 Million USD | -93.24% |
| 2009 | -7.16 Million USD | -24.61% |
| 2008 | -15.13 Million USD | 73.49% |
| 2007 | -26.18 Million USD | -59.38% |
| 2006 | -17.37 Million USD | -12.13% |
| 2005 | -15.32 Million USD | -48.04% |
| 2004 | -13.48 Million USD | 7.25% |
| 2003 | -11.28 Million USD | -487.6% |
| 2002 | -3.31 Million USD | -456.39% |
| 2001 | -345.09 Thousand USD | 58.4% |
| 2000 | -829.6 Thousand USD | 95.14% |
| 1999 | -15.2 Million USD | -81.48% |
| 1998 | -7.19 Million USD | -18.99% |
| 1997 | -4.7 Million USD | -5.33% |
| 1996 | -2.8 Million USD | 3.85% |
| 1995 | -8.9 Million USD | -4.0% |
| 1994 | -7.5 Million USD | -141.94% |
| 1993 | -3.1 Million USD | 36.73% |
| 1992 | -2.5 Million USD | -345.0% |
| 1991 | 2.3 Million USD | 355.56% |
| 1990 | -900 Thousand USD | 76.32% |
| 1989 | -3.8 Million USD | 25.49% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -1.29 Million USD | -54.44% |
| 2024 Q1 | -829.84 Thousand USD | 2.95% |
| 2023 Q1 | -1.03 Million USD | -8.85% |
| 2023 Q4 | -879.15 Thousand USD | -4.96% |
| 2023 Q3 | -837.62 Thousand USD | 17.72% |
| 2023 Q2 | -1.01 Million USD | 1.3% |
| 2023 FY | - USD | 22.15% |
| 2022 FY | - USD | 17.93% |
| 2022 Q1 | -1.24 Million USD | 37.16% |
| 2022 Q2 | -1.45 Million USD | -16.7% |
| 2022 Q4 | -947.5 Thousand USD | 15.32% |
| 2022 Q3 | -1.11 Million USD | 23.01% |
| 2021 Q1 | -1.23 Million USD | 10.2% |
| 2021 Q3 | -1.48 Million USD | -31.06% |
| 2021 Q2 | -1.13 Million USD | 8.07% |
| 2021 Q4 | -1.98 Million USD | -33.58% |
| 2021 FY | - USD | 9.6% |
| 2020 Q2 | -1.28 Million USD | -10.95% |
| 2020 Q4 | -1.37 Million USD | 50.11% |
| 2020 Q1 | -1.15 Million USD | 60.73% |
| 2020 Q3 | -2.74 Million USD | -114.07% |
| 2020 FY | - USD | 12.02% |
| 2019 Q3 | -1.48 Million USD | -5.59% |
| 2019 FY | - USD | 4.57% |
| 2019 Q4 | -2.94 Million USD | -98.36% |
| 2019 Q2 | -1.4 Million USD | 15.27% |
| 2019 Q1 | -1.66 Million USD | -226.69% |
| 2018 Q2 | -2.28 Million USD | 38.2% |
| 2018 Q3 | -2.79 Million USD | -22.03% |
| 2018 Q4 | 1.31 Million USD | 146.96% |
| 2018 Q1 | -3.7 Million USD | 25.34% |
| 2018 FY | - USD | 75.35% |
| 2017 FY | - USD | 37.84% |
| 2017 Q2 | -9.03 Million USD | 5.1% |
| 2017 Q1 | -9.51 Million USD | -2.99% |
| 2017 Q3 | -7.91 Million USD | 12.34% |
| 2017 Q4 | -4.95 Million USD | 37.38% |
| 2016 Q3 | -11.64 Million USD | 36.41% |
| 2016 Q2 | -18.3 Million USD | -53.32% |
| 2016 Q4 | -9.23 Million USD | 20.63% |
| 2016 FY | - USD | 23.88% |
| 2016 Q1 | -11.93 Million USD | 47.63% |
| 2015 Q1 | -13.73 Million USD | -10.1% |
| 2015 Q4 | -22.79 Million USD | -61.7% |
| 2015 FY | - USD | 1.57% |
| 2015 Q2 | -16.55 Million USD | -20.57% |
| 2015 Q3 | -14.1 Million USD | 14.85% |
| 2014 FY | - USD | -842.6% |
| 2014 Q4 | -12.47 Million USD | 38.69% |
| 2014 Q3 | -20.34 Million USD | -87.76% |
| 2014 Q2 | -10.83 Million USD | 56.29% |
| 2014 Q1 | -24.78 Million USD | -458.96% |
| 2013 Q3 | -1.99 Million USD | 78.6% |
| 2013 Q2 | -9.3 Million USD | -222.85% |
| 2013 Q4 | 6.9 Million USD | 446.98% |
| 2013 Q1 | -2.88 Million USD | 79.01% |
| 2013 FY | - USD | 69.35% |
| 2012 Q3 | -11.29 Million USD | -400.52% |
| 2012 FY | - USD | 22.73% |
| 2012 Q4 | -13.72 Million USD | -21.49% |
| 2012 Q1 | -2.43 Million USD | 74.31% |
| 2012 Q2 | 3.76 Million USD | 254.36% |
| 2011 Q3 | -9.27 Million USD | -114.15% |
| 2011 FY | - USD | -73.6% |
| 2011 Q4 | -9.48 Million USD | -2.19% |
| 2011 Q1 | -7.48 Million USD | -372.53% |
| 2011 Q2 | -4.33 Million USD | 42.11% |
| 2010 FY | - USD | -93.24% |
| 2010 Q1 | -4.8 Million USD | 15.99% |
| 2010 Q4 | -1.58 Million USD | 67.51% |
| 2010 Q2 | -6.4 Million USD | -33.29% |
| 2010 Q3 | -4.87 Million USD | 23.9% |
| 2009 Q4 | -5.72 Million USD | -318.79% |
| 2009 Q2 | -2.17 Million USD | 43.69% |
| 2009 FY | - USD | -24.61% |
| 2009 Q1 | -3.86 Million USD | -12.84% |
| 2009 Q3 | 2.61 Million USD | 220.21% |
| 2008 Q2 | -3.83 Million USD | 31.06% |
| 2008 FY | - USD | 73.49% |
| 2008 Q4 | -3.42 Million USD | -162.33% |
| 2008 Q3 | 5.49 Million USD | 243.07% |
| 2008 Q1 | -5.56 Million USD | 23.5% |
| 2007 Q4 | -7.27 Million USD | -32.97% |
| 2007 FY | - USD | -59.38% |
| 2007 Q1 | -4.85 Million USD | -7.49% |
| 2007 Q2 | -9.84 Million USD | -102.58% |
| 2007 Q3 | -5.47 Million USD | 44.38% |
| 2006 Q4 | -4.52 Million USD | -47.01% |
| 2006 Q2 | -5.56 Million USD | -31.97% |
| 2006 Q3 | -3.07 Million USD | 44.72% |
| 2006 Q1 | -4.21 Million USD | -12.34% |
| 2006 FY | - USD | -12.13% |
| 2005 Q4 | -3.75 Million USD | -7.97% |
| 2005 Q3 | -3.47 Million USD | 23.3% |
| 2005 Q2 | -4.53 Million USD | -26.92% |
| 2005 Q1 | -3.56 Million USD | -29.2% |
| 2005 FY | - USD | -48.04% |
| 2004 Q1 | -3.91 Million USD | -22.14% |
| 2004 Q4 | -2.76 Million USD | 2.06% |
| 2004 Q2 | -4.31 Million USD | -10.18% |
| 2004 Q3 | -2.82 Million USD | 34.61% |
| 2004 FY | - USD | 7.25% |
| 2003 Q1 | -660.37 Thousand USD | -1357.19% |
| 2003 FY | - USD | -487.6% |
| 2003 Q4 | -3.2 Million USD | -20.84% |
| 2003 Q3 | -2.29 Million USD | 44.64% |
| 2003 Q2 | -4.78 Million USD | -614.53% |
| 2002 Q3 | -1.87 Million USD | 68.08% |
| 2002 Q2 | -702.13 Thousand USD | -588.85% |
| 2002 Q1 | -33.02 Thousand USD | -103.94% |
| 2002 Q4 | -863.15 Thousand USD | 120.31% |
| 2002 FY | - USD | -456.39% |
| 2001 Q3 | -855.64 Thousand USD | 6.55% |
| 2001 Q1 | -960.06 Thousand USD | -147.78% |
| 2001 Q4 | 3.03 Million USD | 376.51% |
| 2001 FY | - USD | 58.4% |
| 2001 Q2 | -1.07 Million USD | -22.16% |
| 2000 Q3 | -806.17 Thousand USD | 4.67% |
| 2000 Q1 | -858.9 Thousand USD | 73.19% |
| 2000 FY | - USD | 95.14% |
| 2000 Q4 | 2 Million USD | 302.15% |
| 2000 Q2 | -883.02 Thousand USD | 21.57% |
| 1999 Q2 | -2.96 Million USD | 13.51% |
| 1999 FY | - USD | -81.48% |
| 1999 Q4 | -4.39 Million USD | 8.17% |
| 1999 Q3 | -5.4 Million USD | -68.75% |
| 1999 Q1 | -3.2 Million USD | -54.17% |
| 1998 Q4 | -2.4 Million USD | -20.0% |
| 1998 FY | - USD | -18.99% |
| 1998 Q1 | -1.4 Million USD | 69.49% |
| 1998 Q2 | -2.3 Million USD | -72.22% |
| 1998 Q3 | -2.3 Million USD | 35.48% |
| 1997 Q1 | -1 Million USD | 58.06% |
| 1997 Q4 | -3.5 Million USD | -436.36% |
| 1997 Q3 | -1.8 Million USD | -37.5% |
| 1997 Q2 | -1.6 Million USD | 38.46% |
| 1997 FY | - USD | -5.33% |
| 1996 Q3 | -1 Million USD | 9.09% |
| 1996 Q2 | -1.1 Million USD | 38.89% |
| 1996 Q1 | -1.5 Million USD | 61.7% |
| 1996 FY | - USD | 3.85% |
| 1996 Q4 | -3.1 Million USD | -210.0% |
| 1995 Q3 | -1.7 Million USD | -54.55% |
| 1995 Q2 | -2.1 Million USD | -175.0% |
| 1995 Q1 | -1.8 Million USD | 81.82% |
| 1995 FY | - USD | -4.0% |
| 1995 Q4 | -3.3 Million USD | -176.47% |
| 1994 Q1 | -1.5 Million USD | 25.0% |
| 1994 Q3 | -1.8 Million USD | 5.26% |
| 1994 Q2 | -1.9 Million USD | -26.67% |
| 1994 FY | - USD | -141.94% |
| 1994 Q4 | -2.2 Million USD | -22.22% |
| 1993 Q3 | -800 Thousand USD | -700.0% |
| 1993 Q1 | -100 Thousand USD | 94.74% |
| 1993 Q2 | -100 Thousand USD | 0.0% |
| 1993 Q4 | -2 Million USD | -150.0% |
| 1993 FY | - USD | 36.73% |
| 1992 Q4 | -1.9 Million USD | -11.76% |
| 1992 Q3 | -1.7 Million USD | -41.67% |
| 1992 Q2 | -1.2 Million USD | -200.0% |
| 1992 Q1 | -400 Thousand USD | 20.0% |
| 1992 FY | - USD | -345.0% |
| 1991 FY | - USD | 300.0% |
| 1991 Q4 | -500 Thousand USD | -150.0% |
| 1991 Q1 | 600 Thousand USD | 300.0% |
| 1991 Q2 | 1.1 Million USD | 83.33% |
| 1991 Q3 | 1 Million USD | -9.09% |
| 1990 Q4 | -300 Thousand USD | -200.0% |
| 1990 Q3 | -100 Thousand USD | 0.0% |
| 1990 Q1 | -500 Thousand USD | -400.0% |
| 1990 Q2 | - USD | 100.0% |
| 1990 FY | - USD | 73.68% |
| 1989 FY | - USD | 29.63% |
| 1989 Q3 | -500 Thousand USD | -600.0% |
| 1989 Q2 | 100 Thousand USD | 0.0% |
| 1989 Q1 | 100 Thousand USD | 101.59% |
| 1989 Q4 | -100 Thousand USD | 80.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 100.58% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 106.954% |
| SQZ Biotechnologies Company | -64.14 Million USD | 100.643% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 102.374% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 99.562% |
| Mesoblast Limited | -62.38 Million USD | 100.661% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 126.84% |
| Genus plc | 73.7 Million USD | 99.441% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 106.236% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 111.623% |
| Marizyme, Inc. | -34.28 Million USD | 101.203% |
| ContraFect Corporation | -64.99 Million USD | 100.634% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 104.7% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 109.109% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 129.411% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 115.591% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 117.742% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | 179.584% |
| Accustem Sciences Inc. | -3.74 Million USD | 111.005% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 100.855% |
| EV Biologics, Inc. | -1.26 Million USD | 132.537% |
| Q BioMed Inc. | -617.62 Thousand USD | 166.753% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 88.458% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 165.193% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 118.047% |
| Biomind Labs Inc. | -1.03 Million USD | 139.851% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 95.826% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 105.757% |
| Skye Bioscience, Inc. | -13.54 Million USD | 103.043% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 127.718% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 1749.132% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 110.614% |
| IMV Inc. | -35.52 Million USD | 101.161% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 102.598% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 116.478% |
| GB Sciences, Inc. | -1.41 Million USD | 129.036% |
| Alpha Cognition Inc. | -9.7 Million USD | 104.248% |
| HST Global, Inc. | -5303.00 USD | 7874.524% |
| CSL Limited | 4.78 Billion USD | 99.991% |
| Halberd Corporation | -74.27 Thousand USD | 655.047% |
| Enzolytics Inc. | -2.12 Million USD | 119.429% |
| Resverlogix Corp. | -11.74 Million USD | 103.511% |
| Affymax, Inc. | -14.29 Million USD | 102.884% |
| SYBLEU INC | -141.57 Thousand USD | 391.22% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 113.46% |
| argenx SE | -216.02 Million USD | 100.191% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 100.745% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 66.123% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 127.506% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | -8.827% |
| AVAX Technologies, Inc. | -6.11 Million USD | 106.745% |
| Zenith Capital Corp. | -8.6 Million USD | 104.791% |
| Genscript Biotech Corporation | -248.71 Million USD | 100.166% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 2466.586% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 116.852% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | 334.219% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 101.04% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 114.254% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | 139.403% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | -6031.514% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 123.559% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 121.463% |
| BioStem Technologies, Inc. | -7.55 Million USD | 105.458% |
| ONE Bio Corp. | 13.61 Million USD | 96.971% |
| Reve Technologies, Inc. | -181.08 Thousand USD | 327.67% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 120.043% |
| Agentix Corp. | -1.37 Million USD | 130.055% |
| Cell Source, Inc. | -4.27 Million USD | 109.65% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | 212.271% |
| Regen BioPharma, Inc. | 1.46 Million USD | 71.876% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | 144.003% |
| NovAccess Global Inc. | -1.03 Million USD | 139.842% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 95.343% |
| Itoco Inc. | -1.86 Million USD | 122.059% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | 208.604% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 136.943% |
| Kadimastem Ltd | -2.62 Million USD | 115.71% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | 272.395% |
| CytoDyn Inc. | -18.02 Million USD | 102.287% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | 621.686% |
| Mobile Lads Corp. | -2.24 Million USD | 118.396% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | 3471.355% |
| Qrons Inc. | -40.08 Thousand USD | 1128.625% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | 184.888% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 21.832% |
| Rebus Holdings, Inc. | -951 Thousand USD | 143.353% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | 138.821% |
| International Stem Cell Corporation | 202 Thousand USD | -104.1% |
| Bioxytran, Inc. | -3.82 Million USD | 110.792% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 883.212% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 116.746% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 101.149% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -45 Thousand USD | 1016.184% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 115.058% |
| Neutra Corp. | -181.24 Thousand USD | 327.47% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 102.045% |
| PureTech Health plc | -11.62 Million USD | 103.546% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 102.045% |
| IXICO plc | -707 Thousand USD | 158.314% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 105.365% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 100.853% |
| CSL Limited | 4.73 Billion USD | 99.991% |
| Cellectis S.A. | -92.63 Million USD | 100.445% |